1.Linker Design Impacts Antibody-DrugConjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol. 2021; 12: 687926.
1.Linker Design Impacts Antibody-DrugConjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol. 2021; 12: 687926. 公众号内回复“肿瘤免疫”或扫描下方图片中的二维码免费下载《小药说药肿瘤免疫全集》的PDF格式电子书! 公众号已建立“小药说药专业交流群...
1.Linker Design Impacts Antibody-DrugConjugate Pharmacokinetics and EfficacyviaModulating the Stability and Payload Release Efficiency. Front Pharmacol.2021; 12: 687926. 注:图文来源于网络 http://weixin.qq.com/r/zRNdRe3EZ7AYrakm90bf (二维码自动识别)...
1.Linker Design Impacts Antibody-DrugConjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol. 2021; 12: 687926.
此外,建议将集成连接子设计与剂量设计相结合,以找到理想疗效和最小毒性的最佳剂量方案。 参考文献: 1.Linker Design Impacts Antibody-DrugConjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol. 2021; 12: 687926....
抗体药物偶联物(Antibody-Drug Conjugate,ADC)结合了单克隆抗体的肿瘤靶向特异性和细胞毒性药物(Warhead/Payload)的强效细胞杀伤活性,通过精心设计的化学接头(Linker)将二者偶联在一起,在实现精确定位的同时展现出强大的抗肿瘤活性,以改善Warhead的治疗窗口[1]。基于ADC药物的临床成功[2],研究人员对设计新样式的ADC的兴...
总结起来,双载荷ADC及其类似物的构建:一种是利用两个反应位点分步进行构建;另一种就是利用单一反应位点引入分支Linker,再通过点击化学组装细胞毒性药物。虽然双载荷ADC构建方法目前已经较为成熟,但其药动药代方面的方面任重道远。 主要参考文献 1. Fu, Z., et ...
抗体药物偶联物(Antibody-Drug Conjugate,ADC)结合了单克隆抗体的肿瘤靶向特异性和细胞毒性药物(Warhead/Payload)的强效细胞杀伤活性,通过精心设计的化学接头(Linker)将二者偶联在一起,在实现精确定位的同时展现出强大的抗肿瘤活性,以改善Warhead的治疗窗口[1]。基于ADC药物的临床成功[2],研究人员对设计新样式的ADC的兴...
Abstract 1529: Characterizing antibody internalization for rational selection of ADC linker designdoi:10.1158/1538-7445.AM2023-1529Antibody-drug conjugates (ADC), which target a highly potent cytotoxin to a specific protein overexpressed on tumor cells, are a promising class of anticancer therapeutics. ...
抗体药物偶联物(ADC)偶联肿瘤抗原特异性单克隆抗体mAb、稳定的化学linker与强效细胞毒素,将单抗的选择性与化疗药物的细胞毒性潜力相结合。这三种组分共同产生了一种强大的溶瘤剂,能够在抗体对肿瘤靶标的高亲和力的引导下,特异性地将正常耐受的细胞毒性药物递送到癌细胞(图1)。